Asia-Pacific Prostate Cancer Diagnostics Market - Industry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET END USERS COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
5 COMPARATIVE ANALYSIS WITH PARENT MARKET
6 REGULATORY FRAMEWORK: ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET
6.1 REGULATORY SCENARIO IN THE U.S.
6.2 REGULATORY SCENARIO IN EUROPEAN UNION
6.3 REGULATORY SCENARIO IN JAPAN
6.4 REGULATORY SCENARIO IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF PROSTATE CANCER
7.1.2 INCREASE RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTIC
7.1.3 INCREASE IN GERIATRIC POPULATION
7.1.4 LAUNCH OF NEW PRODUCTS FOR PROSTATE CANCER DIAGNOSTIC
7.1.5 DISEASE CAUSING PROSTATE CANCER
7.2 RESTRAINTS
7.2.1 CONTROVERSY RELATED TO PSA TESTING
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE
7.2.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.3 OPPORTUNITIES
7.3.1 RISING INVESTMENT AND FUNDING BY EMERGING PLAYERS
7.3.2 REIMBURSEMENT POLICY FOR PROSTATE CANCER DIAGNOSIS
7.3.3 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
7.3.4 RISING SURVIVAL RATE DUE TO EARLY DIAGNOSIS OF PROSTATE CANCER
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY REQUIREMENT FOR DIAGNOSTIC PRODUCTS
7.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTICS TESTS
7.4.3 INACCURATE DIAGNOSIS RESULTS
8 IMPACT OF COVID-19 ON ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION BY MANUFACTURERS MADE DURING COVID-19 PANDEMIC
8.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.6 CONCLUSION
9 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 REAGENTS & CONSUMABLES
9.3 INSTRUMENTS
9.4 ACCESSORIES
10 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE
10.1 OVERVIEW
10.2 PRELIMINARY SCREENING TESTS
10.2.1 PROSTATE-SPECIFIC ANTIGEN (PSA) TEST
10.2.2 DIGITAL RECTAL EXAM (DRE) TEST
10.3 CONFIRMATORY TESTS
10.3.1 PCA3 TEST
10.3.2 BIOPSY
10.3.3 IMAGING TESTS
10.3.3.1 ULTRASOUND
10.3.3.2 MAGNETIC RESONANCE IMAGING (MRI)
10.3.3.2.1 MULTIPARAMETRIC MRI
10.3.3.2.2 MRI FUSION-GUIDED PROSTATE BIOPSY
10.3.3.3 CT SCAN
10.3.3.4 BONE SCAN
10.3.3.5 PET/CT SCAN
10.3.4 BIOMARKER
10.3.4.1 RNA BIOMARKERS
10.3.4.2 DNA BIOMARKERS
10.3.4.3 PROTEIN BIOMARKERS
11 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE
11.1 OVERVIEW
11.2 PROSTATIC ADENOCARCINOMA
11.3 SMALL CELL CARCINOMA
11.4 OTHERS
12 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP
12.1 OVERVIEW
12.2 GERIATRICS
12.3 ADULT
12.4 PEDIATRIC
13 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE
13.1 OVERVIEW
13.2 LOCALIZED PROSTATE CANCER
13.3 RECURRENT/ADVANCED PROSTATE CANCER
13.4 CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC)
14 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE
14.1 OVERVIEW
14.2 BLOOD
14.3 TISSUE
14.4 URINE
14.5 OTHERS
15 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS
15.1 OVERVIEW
15.2 INDEPENDENT DIAGNOSTIC LABORATORIES
15.3 HOSPITALS
15.4 CLINICS
15.5 AMBULATORY SURGICAL CENTERS
15.6 CANCER RESEARCH INSTITUTES
15.7 OTHERS
16 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
17 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
17.1 ASIA - PACIFIC
17.1.1 CHINA
17.1.2 JAPAN
17.1.3 INDIA
17.1.4 AUSTRALIA
17.1.5 SOUTH KOREA
17.1.6 SINGAPORE
17.1.7 THAILAND
17.1.8 MALAYSIA
17.1.9 INDONESIA
17.1.10 PHILIPPINES
17.1.11 REST OF ASIA - PACIFIC
18 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT
20 COMPANY PROFILE
20.1 F. HOFFMANN-LA ROCHE LTD
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLI0
20.1.5 RECENT DEVELOPMENTS
20.2 ABBOTT
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 SIEMENS HEALTHCARE GMBH
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 OPKO HEALTH INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 ACCUQUIK TEST KITS
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 ACON LABORATORIES INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENTS
20.8 BIOMERIEUX SA
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 DIASORIN S.P.A
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLI0
20.9.4 RECENT DEVELOPMENTS
20.10 EUROLYSER DIAGNOSTICA GMBH
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENT
20.11 FUJIREBIO
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLI
20.11.3 RECENT DEVELOPMENTS
20.12 GENOMIC HEALTH, INC., (A SUBSIDIARY OF EXACT SCIENCES CORPORATION)
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENTS
20.13 HOLOGIC, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 HUMASIS
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 MDXHEALTHCARE
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 METAMARK GENETICS, INC.
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLI0
20.16.3 RECENT DEVELOPMENTS
20.17 MYRAID GENETICS, INC.
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE ANALYSIS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENTS
20.18 PROSTATYPE GENOMICS
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 PROTEOMEDIX
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENTS
20.20 TECO DIAGNOSTICS
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS